MEDICAL IMPLANT
Disclosed is a self-expanding medical implant for placement within a lumen of a patient. The implant comprises a woven or non-woven structure having a substantially tubular configuration, and is designed to be low-profile such that it is deliverable with a small diameter catheter. The implant has a high recoverability and desired mechanical properties.
1 . A polymer coating composition prepared by a process comprising the steps of:
dissolving poly (lactic acid-co-caprolactone) in a solvent to form a solution;
adding a diisocyanate crosslinker to the solution; and
curing said solution;
wherein said solution does not comprise a catalyst.
2 . The polymer coating composition of claim 1 , wherein said diisocyanate crosslinker is hexamethylene diisocyanate.
3 . The polymer coating composition of claim 1 , wherein said poly (lactic acid-co-caprolactone) comprises about 50 weight percent of lactic acid and about 50 weight percent of caprolactone.
4 . The polymer coating composition of claim 1 , wherein said solution comprises about 0.125 mL of said diisocyanate crosslinker to every 1.0 grams of poly (lactic acid-co-caprolactone).
5 . The polymer coating composition of claim 4 , wherein said diisocyanate crosslinker is hexamethylene diisocyanate.
6 . The polymer coating composition of claim 4 , wherein said solution comprises about 19.875 mL of a solvent to every 1.0 grams of poly (lactic acid-co-caprolactone).
7 . The polymer coating composition of claim 6 , wherein said solvent comprises methylene chloride.
8 . A medical implant comprising a coating, said coating prepared by a process comprising the steps of:
dissolving poly (lactic acid-co-caprolactone) in a solvent to form a solution;
adding a diisocyanate crosslinker to the solution; and
curing said solution;
wherein said solution does not comprise a catalyst.
9 . The medical implant of claim 8 , wherein said diisocyanate crosslinker is hexamethylene diisocyanate.
10 . The medical implant of claim 8 , wherein said poly (lactic acid-co-caprolactone) comprises about 50 weight percent of lactic acid and about 50 weight percent of caprolactone.
11 . The medical implant of claim 8 , wherein said solution comprises about 0.125 mL of said diisocyanate crosslinker to every 1.0 grams of poly (lactic acid-co-caprolactone).
12 . The medical implant of claim 11 , wherein said diisocyanate crosslinker is hexamethylene diisocyanate.
13 . The medical implant of claim 11 , wherein said solution comprises about 19.875 mL of a solvent to every 1.0 grams of poly (lactic acid-co-caprolactone).
14 . The medical implant of claim 13 , wherein said solvent comprises methylene chloride.
15 . The medical implant of claim 8 , wherein said implant comprises polymeric strands coated with said coating.
16 . The medical implant of claim 15 , wherein said strands comprise poly(lactic acid co-glycolic acid).
17 . The medical implant of claim 16 , wherein said poly(lactic acid co-glycolic acid) comprises about 85 weight percent of lactic acid and about 15 weight percent of glycolic acid.
18 . A medical implant comprising a coating, said implant prepared by a process comprising the steps of:
providing an implant comprising braided polymeric strands;
dissolving poly (lactic acid-co-caprolactone) in a solvent to form a solution;
adding a diisocyanate crosslinker to the solution;
coating said solution onto said polymeric strands; and
curing said solution;
wherein said solution does not comprise a catalyst.
19 . The medical implant of claim 18 , wherein said polymeric strands are biodegradable.
20 . The medical implant of claim 19 , wherein said strands comprise poly(lactic acid co-glycolic acid).
21 . The medical implant of claim 20 , wherein said poly(lactic acid co-glycolic acid) comprises about 85 weight percent of lactic acid and about 15 weight percent of glycolic acid.
22 . The medical implant of claim 18 , wherein said diisocyanate crosslinker is hexamethylene diisocyanate.
23 . The medical implant of claim 18 , wherein said poly (lactic acid-co-caprolactone) comprises about 50 weight percent of lactic acid and about 50 weight percent of caprolactone.
24 . The medical implant of claim 18 , wherein said solution comprises about 0.125 mL of said diisocyanate crosslinker to every 1.0 grams of poly (lactic acid-co-caprolactone).
25 . The medical implant of claim 24 , wherein said diisocyanate crosslinker is hexamethylene diisocyanate.